Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation  by Chiorean, Elena G et al.
D
D
M
H
I
l
m
t
l
a
k
l
d
c
c
Biology of Blood and Marrow Transplantation 10:171-177 (2004)
 2004 American Society for Blood and Marrow Transplantation
1083-8791/04/1003-0003$30.00/0
doi:10.1016/j.bbmt.2003.10.004
Bonor Chimerism Does Not Predict Response to
onor Lymphocyte Infusion for Relapsed Chronic
yelogenous Leukemia after Allogeneic
ematopoietic Cell Transplantation
Elena G. Chiorean,1,2 Todd E. DeFor,1 Daniel J. Weisdorf,1,2 Bruce R. Blazar,1,3 Philip B. McGlave,1,2
Linda J. Burns,1,2 Charlotte Brown,4 Jeffrey S. Miller1,2
1Blood and Marrow Transplant Program; 2Division of Medical, and 3Pediatric Hematology, Oncology and
Transplantation; and 4Department of Laboratory Medicine and Pathology, University of Minnesota,
Minneapolis, Minnesota
Correspondence and reprint requests: Jeffrey S. Miller, MD, Department of Medicine, University of Minnesota
Cancer Center, MMC 806, Division of Hematology, Oncology and Transplantation, Harvard St. at E. River Rd.,
Minneapolis, MN 55455 (e-mail: mille011@umn.edu).
Received April 25, 2003; accepted October 14, 2003
ABSTRACT
We studied the effect of donor chimerism level on the outcome of donor lymphocyte infusion (DLI) therapy
in 42 patients with persistent or relapsed hematologic malignancies after non–T cell–depleted allogeneic
hematopoietic cell transplantation. Seventy-five percent of chronic myelogenous leukemia (CML) and 39% of
non-CML patients entered remission after DLI therapy. Remission and survival rates were similar for CML
patients irrespective of their pre-DLI donor chimerism levels; however, remission occurred sooner in patients
with >10% pre-DLI donor chimerism. None of the non-CML patients with <10% pre-DLI donor chimerism
and 47% of those with>10% pre-DLI donor chimerism attained remission. The 2-year survival rates after DLI
were 75% for CML and 17% for non-CML patients. We conclude that a low level of donor marrow chimerism
is not an adverse prognostic factor for response to DLI in CML patients, but for non-CML patients it may
confer worse outcomes. Better methods to augment the response to DLI for patients with hematologic
malignancies other than CML that recur after allogeneic hematopoietic cell transplantation are needed,
whereas for relapsed CML patients, combination therapies including imatinib mesylate or other promising
antileukemic agents may provide outcomes superior to those with DLI alone.
© 2004 American Society for Blood and Marrow Transplantation
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Donor lymphocyte infusions (DLI) can produce
asting remissions in patients with relapsed chronic
yelogenous leukemia (CML) after allogeneic hema-
opoietic cell transplantation (HCT), but they work
ess well for other malignancies [1,2]. This form of
doptive immunotherapy induces a graft-versus-leu-
emia effect (GVL) mediated by graft-versus-host al-
oreactive donor T cells [1,3]. Persistent or recurring
isease after allogeneic HCT reﬂects a state of mixed
himerism in which infusion of donor lymphocytes
ould overcome the persistence of recipient cells and r
B&MTediate a leukemia-speciﬁc or an allospeciﬁc GVL
esponse [4]. DLI therapy can also cause complica-
ions such as severe graft-versus-host disease (GVHD)
nd myelosuppression, which occur in up to 40% of
atients, and the mortality attributed to DLI therapy
ay be as high as 18% at 2 years after DLI [1,2].
Variables known to have a positive inﬂuence on
urvival after DLI therapy include underlying CML
rather than other hematologic malignancies) and
chievement of complete remission (CR) [1,5]. The
resence of donor T lymphocytes may correlate with
chievement of remission after DLI for patients who
elapse after lymphocyte-depleted bone marrow trans-
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1lantation [6]. In this study, we describe the effect of
he pre-DLI donor chimerism level on remission, sur-
ival, and toxicities after DLI therapy for relapsed
ematologic malignancies in recipients of T cell–re-
lete allogeneic HCT.
ATERIALS AND METHODS
atients
Forty-two patients received DLI at our institution
etween July 1993 and December 1999. Written, in-
ormed consent was obtained from all patients and
onors, and the study was approved by the Committee
n the Use of Human Subjects in Research at the
niversity of Minnesota. Twenty-four patients had
ML, 10 had acute myelogenous leukemia, 6 had
yelodysplastic syndrome, 1 had acute lymphocytic
eukemia, and 1 had juvenile myelomonocytic leuke-
ia. Patients had received T cell–replete HCT from
LA-matched siblings (n  34), a 1 antigen–mis-
atch sibling (n  1), or HLA-matched (n  7)
nrelated donors. Among 18 non-CML patients, 11
eceived chemotherapy a median of 75 days (range,
0-144 days) before DLI, and 4 patients (36%) at-
ained CR attributable to chemotherapy before DLI.
hree CML patients (12%) and 3 non-CML patients
17%) had received multiple courses of DLI (median,
) for persistent or progressive disease. Two (67%) of
he 3 CML patients and none of the 3 non-CML
atients attained CR. If a patient received multiple
ourses of DLI, the date of the last DLI before CR
as attained was considered in evaluating outcomes. If
patient had not attained CR, the date of the ﬁrst
dministered DLI course was considered in evaluating
utcomes. For the 2 CML patients who attained CR,
he initial DLI course was 4 and 8 months before the
uccessful DLI, respectively, and both patients at-
ained CR 5 months later. Patient characteristics are
hown in Table 1. The date of the last follow-up was
une 2002 or the date of last contact with a patient.
onor Lymphocyte Infusions
Donor lymphocytes from the original donor were
btained by lymphapheresis. Before 1996, CML and
on-CML patients received 3 lymphapheresis prod-
cts, irrespective of the cell dose. Starting in February
996, all CML patients received a ﬁxed dose of 1 
08 CD3 T cells per kilogram (n  8), whereas
on-CML patients received 3 lymphapheresis prod-
cts. No patients were receiving immunosuppressive
edications at the time of DLI.
efinitions of Outcomes
CR of leukemia was deﬁned as the normalization
f blood counts and marrow cellularity, the absence of
ny morphologic evidence of leukemia on peripheral t
72lood and marrow evaluation, and the absence of
ytogenetic abnormalities. For patients with CML,
R was deﬁned as complete cytogenetic remission
0% Ph cells and no other cytogenetic abnormalities)
nd molecular remission (no BCR/ABL messenger
NA detected by reverse transcription-polymerase
hain reaction [PCR] analysis). All the CML and non-
ML patients deemed in CR also had evidence of
00% donor chimerism.
Chimerism was evaluated by quantitative PCR of
nformative polymorphic variable number tandem re-
eat regions [7]. Posttransplantation genomic DNA
solated from recipient bone marrow mononuclear
ells was ampliﬁed with ﬂuorescent PCR primers for
ariable number tandem repeat regions found to dis-
inguish donor from recipient alleles. The ﬂuorescent
CR products were separated by gel electrophoresis
n an Applied Biosystems 373 Sequencer (Applied
iosystems, Foster City, CA). The GeneScan software
Applied Biosystems) package was used to correlate
llele peak areas with the percentage of donor or
ecipient DNA. The chimerism assay can detect a
inimum of 5% donor-derived DNA on a recipient
NA background.
Complete donor chimerism was deﬁned as the
resence of 100% donor-derived hematopoietic cells,
nd mixed chimerism was deﬁned as the presence of a
ixture of donor and recipient hematopoietic cells on
one marrow analysis. We chose a cutoff of 10% for
he donor chimerism analysis to compare patients who
ad only minor donor chimerism with those who had
larger fraction of donor cells present at the time of
able 1. Patient Characteristics
Characteristic CML Non-CML
24 18
ge (y), median (range) 37 (21-52) 31 (2-58)
ex
Female 11 (46%) 9 (50%)
Male 13 (54%) 9 (50%)
onor type
Matched sibling 20 (83%) 14 (78%)
Matched unrelated 2 (8%) 3 (17%)
Mismatched sibling 1 (4%) 0
Mismatched unrelated 1 (4%) 1 (5%)
ransplant graft
T-cell replete 21 (87%) 13 (72%)
T-cell depleted 3 (13%) 5 (28%)
cute GVHD after transplantation
(grade II-IV) 13 (54%) 4 (22%)
hronic GVHD after transplantation 10 (42%) 5 (28%)
ime from transplantation to
relapse, mo, median (range) 12 (3-168) 6.5 (1.0-37)
ime from transplantation to
relapse <1 y 9 (37%) 15 (83%)
ime from relapse to DLI, d,
median (range) 78 (8-254) 74.5 (8-119)he DLI infusion. The cutoff of 10% is a value close to
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Effect of Donor Chimerism on DLI Response
Bhe median pre-DLI donor chimerism level for the
ML patients (8.45%) and therefore thought to be
elevant for analysis. Chimerism analyses of peripheral
lood were not considered for categorization in this
tudy.
The clinical manifestations of acute GVHD were
raded I to IV according to criteria described by
homas et al. [8], and chronic GVHDwas classiﬁed as
imited or extensive (requiring treatment), as de-
cribed by Shulman et al. [9]. GVHD that occurred
3 months after HCT or DLI was deﬁned as acute,
nd beyond 3 months it was deﬁned as chronic.
tatistical Analysis
The estimation of survival and relapse-free sur-
ival was calculated by the Kaplan-Meier method.
urvival was measured from the time of the last DLI
ntil death or last follow-up [10]. Relapse-free survival
as measured from the time of conﬁrmed CR until
elapse, death, or last follow-up, whichever came ﬁrst.
he cumulative incidence of CR was calculated by
reating deaths without attaining remission as a com-
eting risk [11]. The statistical comparisons among
actors were completed by the log-rank test. For com-
arisons among factors with n 5 in a group, we used
he Fisher exact test. Univariate analyses were per-
ormed for the factors of pre-DLI donor chimerism,
LI dose, age, time from transplantation to relapse
nd from relapse to DLI, acute and chronic GVHD
fter DLI, CR after DLI, and relapse phase at DLI
for CML patients). Acute and chronic GVHD were
ested as time-dependent factors in a Cox regression
odel [12].
ESULTS
ll Patients
Twenty ﬁve (60%) of 42 patients achieved CR
fter DLI. Eighteen (72%) of the 25 patients had
ML, and 7 patients (28%) had non-CML diseases (6
Figure 1. Survival after DLI for CML and non-CML patients.atients with acute myelogenous leukemia and 1 pa- p
B&MTient with myelodysplastic syndrome). As previous
tudies have shown, patients treated for relapsed CML
ave higher survival rates compared with those treated
or relapsed non-CML diseases (Figure 1). Because of
arked differences in survival, all subsequent analyses
re based on the 2 groups of patients: those with CML
nd non-CML diseases.
atients with CML
Eighteen (75%) of 24 CML patients (95% conﬁ-
ence interval, 50%-100%) achieved molecular remis-
ion after DLI; this was conﬁrmed by conversion to
egative BCR/ABL status by PCR analysis. The me-
ian survival was 54 months (range, 14-79 months) for
atients who achieved CR (n  18), versus 6 months
range, 2.6-35 months) for those who did not obtain
R after DLI (n  6; P .01). The median time to
R was 104 days (range, 35-279 days) after DLI. Two
atients (11%) relapsed 3.5 and 65 months after CR
as documented. The ﬁrst patient died of respiratory
ailure secondary to radiation pneumonitis 5 months
fter relapse, and the other was treated with another
ourse of DLI and is still alive with chronic-phase
ML 7 months after relapse. Sixteen patients (67%)
emain alive in CR after a median follow-up of 59
onths (range, 30-79 months). Five years after DLI,
ML patients had an overall probability of survival of
5% (range, 58%-92%), and for those who attained
R, the relapse-free survival was 94% (range, 82%-
00%).
Effect of chimerism on remission and survival of CML
atients. Because the donor chimerism level may pre-
ict the response to DLI [6], we compared remission
nd survival rates for CML patients with 10% or
10% donor chimerism at the time of DLI (pre-DLI
onor chimerism). Survival rates at 5 years after DLI
ere similar for CML patients with 10% or 10%
re-DLI donor chimerism, as shown in Figure 2. CR
as attained by 10 (77%) of 13 CML patients with
10% and by 8 (73%) of 11 patients with 10%
re-DLI donor chimerism. Patients with 10% chi-
igure 2. Overall survival after DLI for CML patients based on the
re-DLI donor chimerism.
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1erism achieved CR later (median, 5.6 months; range,
.6-9.2 months) than those with 10% pre-DLI do-
or chimerism (median, 3 months; range, 1-5.8
onths; P  .05). Although chimerism level may
eﬂect leukemia cell burden, a more detailed analysis
howed that high CR rates were obtained for all CML
atients irrespective of the chimerism subgroups (Fig-
re 3). Among the patients who achieved CR, the
urvival rates and risk of relapse were similar irrespec-
igure 3. Complete response rates based on the pre-DLI donor
himerism levels (CML patients: n  4 for 0%, n  9 for 1%-9%,
 5 for 10%-50%, and n  6 for 51%-100% pre-DLI donor
himerism; non-CML patients: n  1 for 0%, n  2 for 1%-9%,
 2 for 10%-50%, and n  13 for 51%-100% pre-DLI donor
himerism).
able 2. Factors Inﬂuencing Remission after DLI
Factor
CML P
n
Cumulative In
of CR at 1 y (
re-DLI donor chimerism
<10% 13 77% (54-1
>10% 11 73% (50-9
LI dose (NC/kg)
<4  108 13 92% (64-1
>4  108 10 60% (29-9
ge (y)
<35 11 91% (60-1
>35 13 50% (21-7
ime from transplantation to relapse
<1 y/6 mo (CML/non-CML) 9 44% (13-7
>1 y/6 mo 15 87% (57-1
ime from relapse to DLI (mo)
<2 8 73% (46-1
>2 16 69% (43-1
cute GVHD after DLI
Yes 7 71% (38-1
No 17 69% (43-9
hronic GVHD after DLI
Yes 10 70% (38-1
No 14 69% (41-9
ML phase at relapse
Cytogenetic only 7 100%
Hematologic 17 65% (39-9A indicates not applicable; NS, P .20; CI, conﬁdence interval; NC, nu
74ive of the pre-DLI donor chimerism. The median
re-DLI donor chimerism for the CML patients who
ttained CR was 5%, compared with 10% for those
ho did not achieve CR.
Effect of chimerism on GVHD and aplasia. Overall,
VHD developed in 17 (71%) of 24 CML patients
fter HCT and in 12 patients (50%) after DLI.
mong the 17 patients who had acute and/or chronic
VHD after HCT, 13 (76%) achieved CR after DLI,
ompared with 5 (71%) of 7 patients without GVHD
fter HCT (P not signiﬁcant). CR rates were similar
or the patients in whom GVHD did or did not de-
elop after HCT or DLI or both (data not shown; P
ot signiﬁcant).
Acute GVHD (grade II to IV) occurred in 2 (15%)
f 13 CML patients with 10% pre-DLI donor chi-
erism and in 5 (45%) of 11 patients with 10%
re-DLI donor chimerism (P .11). Chronic GVHD
ecessitating treatment developed in 5 (38%) of 13
ML patients with 10% and in 5 (45%) of 11
atients with 10% pre-DLI donor chimerism (P 
ot signiﬁcant). Remission (Table 2) and 5-year sur-
ival rates (Table 3) were similar among patients with
r without acute or chronic GVHD.
None of the patients with 10% pre-DLI donor
himerism, but 2 of 13 CML patients (15%), both
ith 5% pre-DLI donor chimerism levels, developed
one marrow aplasia 1 and 4 months after the last
ourse of DLI, without any associated GVHD. Both
Non-CML Patients
e
) P Value n
Cumulative Incidence
of CR at 1 y (95% CI) P Value
.05 3 0 .20
15 47% (22-72)
.09 6 33% (0-70) NS
10 40% (10-70)
.11 10 60% (30-90) .07
8 12% (0-34)
.07 9 44% (11-77) NS
9 60% (25-95)
NS 8 38% (6-70) NS
10 40% (10-70)
NS 6 67% (29-100) .10
12 25% (0-50)
NS 4 75% (32-100) .05
14 29% (5-54)
.09 NA NA —atients
cidenc
95% CI
00)
6)
00)
1)
00)
9)
5)
00)
00)
00)
00)
5)
00)
7)
1)cleated cells.
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Effect of Donor Chimerism on DLI Response
Batients had received 2 courses (3 doses each) of DLI
efore pancytopenia developed, with total corre-
ponding doses of 12  108 and 7  108 nucleated
ells per kilogram. Both patients were in CR at the
ime of pancytopenia, received marrow and peripheral
lood stem cell support with antithymocyte globulin
reinfusion conditioning, and remain alive in CR at 27
nd 71 months after DLI. These data are concordant
ith prior observations that residual donor hemato-
oiesis in relapsed patients may protect from DLI-
nduced bone marrow aplasia [13].
atients with Non-CML Malignancies
The overall probability of survival for non-CML
atients was 17% (95% conﬁdence interval, 0%-34%)
t 2 years after DLI (Figure 1). Seven (39%) of 18
on-CML patients achieved CR. Among them, 4
36%) of 11 patients pretreated with chemotherapy
chieved CR before DLI and had a median survival of
0 months (range, 2.6-97 months). Three (43%) of 7
atients treated with DLI without prior induction
hemotherapy attained CR at a median of 29 days
able 3. Factors Inﬂuencing Survival after DLI
Factor
CML
n
5-y Sur
(95% C
verall 24 75% (58%
re-DLI donor chimerism
<10% 13 77% (54%
>10% 11 73% (48%
LI dose (NC/kg)
<4  108 13 92% (76%
>4  108 10 60% (30%
ge (y)
<35 11 91% (74%
>35 13 62% (36%
ime from transplantation to relapse
<1 y/6 mo (CML/non-CML) 9 67% (36%
>1 y/6 mo 15 80% (60%
ime from relapse to DLI (mo)
<2 8 75% (45%
>2 16 75% (54%
cute GVHD after DLI
Yes 7 71% (37%
No 17 76% (56%
hronic GVHD after DLI
Yes 10 80% (55%
No 14 71% (57%
R after DLI
Yes 18 94% (84%
No 6 0
elapse phase at DLI (CML)
Cytogenetic only 7 100%
Hematologic 17 65% (42%
A indicates not applicable; NS, P .20; CI, conﬁdence interval; N
Nine CML patients were evaluable 5 y after DLI administration.
Three non-CML patients were evaluable 2 y after DLI administr
Four non-CML patients were in CR from induction chemotheraprange, 27-70 days) after DLI and had a median sur- c
B&MTival of 5 months (range, 2.6-36 months). Three non-
ML patients were treated with multiple courses of
LI; 2 never attained CR, whereas 1 patient was in
R from chemotherapy before DLI.
None of the 3 patients with10% pre-DLI donor
himerism and 7 (47%) of 15 patients with 10%
onor chimerism attained CR (P  .25). Moreover,
one of the patients with 50% and 54% of those
ith 50% pre-DLI donor chimerism attained CR
Figure 3), but the difference was not statistically sig-
iﬁcant (P  .10). Survival rates were also similar for
on-CML patients with 10% or 10% pre-DLI
onor chimerism (Table 3). The median chimerism
or the non-CML patients was 94% (range,
%-100%), with 97% (range, 75%-100%) for those
ho attained CR and 65% (range, 0%-100%) for
hose who did not attain CR (P  .08).
Five (28%) of 18 non-CML patients developed
VHD after HCT, and 8 patients (44%) developed
VHD after DLI. None of the 5 patients who had
VHD and 7 (54%) of 13 patients without GVHD
fter HCT achieved CR. Acute (grade II to IV) and
s Non-CML Patients
P Value n
2-y Survival
(95% CI)† P Value
18 17% (0%-34%)
NS 3 0 NS
15 20% (0%-40%)
.07 6 0% NS
10 10% (0%-28%)
.12 10 30% (2%-58%) <.01
8 0%
NS 10 10% (0%-28%) NS
8 25% (0%-55%)
NS 9 22% (0%-49%) NS
9 13% (0%-35%)
NS 6 17% (0%-47%) NS
12 0%
NS 4 50% (0%-100%) .05
14 0
<.01 7‡ 14% (0%-40%) .08
11 0
.09 NA NA
cleated cells.
re DLI.Patient
vival
I)*
-92%)
-100%)
-99%)
-100%)
-90%)
-100%)
-88%)
-98%)
-100%)
-100%)
-96%)
-100%)
-96%)
-100%)
-95%)
-100%)
-85%)
C, nu
ation.hronic GVHD occurred with similar incidence in
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1atients with 10% or 10% pre-DLI donor chi-
erism (33% acute GVHD for both groups and 0%
nd 22% chronic GVHD for the patients with 10%
r 10% donor chimerism, respectively). Notably,
or non-CML patients, both the CR rates and the
-year survival rates were higher for patients who
eveloped chronic GVHD (Tables 2 and 3).
ISCUSSION
DLI can provide a direct GVL effect and offer an
ffective therapy for relapsed hematologic malignan-
ies after hematopoietic stem cell transplantation [14].
ecause DLIs are particularly effective in CML, de-
iding between the use of DLI and alternative thera-
ies, such as the tyrosine kinase inhibitor imatinib
esylate, for relapsed CML patients may be inﬂu-
nced by certain prognostic factors. Relapsed non-
ML diseases have a poor prognosis; only a minority
f patients have a sustained response to DLI. Alter-
atively, a second transplantation can have transplant-
elated mortality of up to 69% [15], and 3-year leu-
emia-free survival rates vary between 11% and 52%,
epending mainly on the interval between the ﬁrst
ransplantation and relapse [15-17]. In an analysis of
on-CML patients only, the best survival after second
CT was observed in patients who were in CR before
eceiving the second HCT and who relapsed beyond
92 days after the ﬁrst HCT [17]. Prior studies have
mphasized that early disease stage [5] and chronic
VHD are correlated with favorable outcomes after
LI [18,19]. The role of the pre-DLI donor chimer-
sm in predicting outcomes after DLI is more contro-
ersial. In patients who relapsed after T cell–depleted
CT, inferior remission rates (15% versus 77%) were
een for those with 40% as compared with 40%
onor T lymphocytes at the time of DLI [6]. Other
uthors have not observed any chimerism inﬂuence on
ttaining CR after DLI [20] or in general outcomes
or patients with multiple myeloma [21].
In this study, we found a small number of relapses
nd high remission and survival rates after DLI in
ML patients, irrespective of the pre-DLI donor chi-
erism levels. In addition, low pre-DLI donor chi-
erism did not increase the risk of relapse in CML
atients. Although a low donor chimerism may merely
e a marker of disease relapse and therefore of worse
utcomes, this was not the case for the CML pa-
ients—outcomes were as good as or better for those
ith lower pre-DLI donor chimerism levels. In con-
rast, for non-CML patients, pre-DLI donor chimer-
sm levels were nonsigniﬁcantly lower (65% versus
7%; P  .08) for the patients who did not attain CR.
The use of DLI as the favored ﬁrst-line therapy in
elapsed CML patients after allogeneic HCT has been
ecently challenged by the speciﬁc inhibitor of the
76CR/ABL tyrosine kinase imatinib mesylate (Gleevec;
ovartis, Atlanta, GA). Recent reports showed en-
ouraging results, with overall response rates as high
s 79% and complete cytogenetic responses of 35%
22,23]. In the study of Kantarjian et al. [22], imatinib
esylate was used in 28 patients, of whom 13 (46%)
eceived DLI a median of 4 months (range, 2-39
onths) before imatinib mesylate. Although it is likely
hat the responses noted in those patients (11 of 13
esponded to imatinib mesylate) were due to imatinib
esylate itself, a DLI inﬂuence cannot be discarded,
ecause it is well described that responses after DLI
ay be protracted and occur as late as 6 to 12 months
fter therapy [2,4]. As we and others report durable
olecular CR after DLI for relapsed CML after allo-
eneic HCT, no long-term series have yet been de-
cribed using imatinib mesylate. For non-CML ma-
ignancies, DLI has more limited efﬁcacy, and
herefore its use in conjunction with induction che-
otherapy or other novel postremission therapies
hould be explored.
In summary, we report that pre-DLI donor chi-
erism levels do not predict either response or sur-
ival and should not be considered a prognostic de-
erminant factoring into the decision-making process
f using DLI for treating relapsed CML after alloge-
eic HCT. Given the long-term excellent outcomes
ith DLI in CML (as shown here), the unknown
urability of responses to imatinib mesylate, and the
stablished differences in toxicity, future strategies
eed to address how to prioritize the use of these
reatments.
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